BRPI1009257A2 - antagonista receptor de mineralocorticoide e métodos de uso. - Google Patents
antagonista receptor de mineralocorticoide e métodos de uso.Info
- Publication number
- BRPI1009257A2 BRPI1009257A2 BRPI1009257A BRPI1009257A BRPI1009257A2 BR PI1009257 A2 BRPI1009257 A2 BR PI1009257A2 BR PI1009257 A BRPI1009257 A BR PI1009257A BR PI1009257 A BRPI1009257 A BR PI1009257A BR PI1009257 A2 BRPI1009257 A2 BR PI1009257A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- receptor antagonist
- mineralocorticoid receptor
- mineralocorticoid
- antagonist
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15957809P | 2009-03-12 | 2009-03-12 | |
| PCT/US2010/026138 WO2010104721A1 (en) | 2009-03-12 | 2010-03-04 | Mineralocorticoid receptor antagonist and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009257A2 true BRPI1009257A2 (pt) | 2016-03-08 |
Family
ID=42139981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009257A BRPI1009257A2 (pt) | 2009-03-12 | 2010-03-04 | antagonista receptor de mineralocorticoide e métodos de uso. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8658638B2 (enExample) |
| EP (1) | EP2406252B1 (enExample) |
| JP (1) | JP5570536B2 (enExample) |
| KR (1) | KR101312179B1 (enExample) |
| CN (1) | CN102333773B (enExample) |
| AU (1) | AU2010222902B2 (enExample) |
| BR (1) | BRPI1009257A2 (enExample) |
| CA (1) | CA2751901C (enExample) |
| EA (1) | EA019179B1 (enExample) |
| ES (1) | ES2542001T3 (enExample) |
| MX (1) | MX2011009506A (enExample) |
| WO (1) | WO2010104721A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
| SI3160948T1 (sl) | 2014-06-30 | 2020-06-30 | Astrazeneca Ab | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida |
| EP3362095B1 (en) | 2015-10-13 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| ES2973248T3 (es) | 2016-07-26 | 2024-06-19 | Inst Nat Sante Rech Med | Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis |
| WO2021180818A1 (en) | 2020-03-11 | 2021-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| CN1918151A (zh) * | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| TWI431010B (zh) | 2007-12-19 | 2014-03-21 | Lilly Co Eli | 礦皮質素受體拮抗劑及使用方法 |
-
2010
- 2010-03-04 WO PCT/US2010/026138 patent/WO2010104721A1/en not_active Ceased
- 2010-03-04 CA CA2751901A patent/CA2751901C/en not_active Expired - Fee Related
- 2010-03-04 JP JP2011554083A patent/JP5570536B2/ja not_active Expired - Fee Related
- 2010-03-04 MX MX2011009506A patent/MX2011009506A/es active IP Right Grant
- 2010-03-04 KR KR1020117021231A patent/KR101312179B1/ko not_active Expired - Fee Related
- 2010-03-04 US US13/203,518 patent/US8658638B2/en not_active Expired - Fee Related
- 2010-03-04 EP EP20100707770 patent/EP2406252B1/en not_active Not-in-force
- 2010-03-04 CN CN201080009314.8A patent/CN102333773B/zh not_active Expired - Fee Related
- 2010-03-04 ES ES10707770.3T patent/ES2542001T3/es active Active
- 2010-03-04 AU AU2010222902A patent/AU2010222902B2/en not_active Ceased
- 2010-03-04 BR BRPI1009257A patent/BRPI1009257A2/pt not_active IP Right Cessation
- 2010-03-04 EA EA201171125A patent/EA019179B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2011009506A (es) | 2011-09-28 |
| JP5570536B2 (ja) | 2014-08-13 |
| CA2751901C (en) | 2013-08-06 |
| AU2010222902B2 (en) | 2013-04-18 |
| KR101312179B1 (ko) | 2013-09-26 |
| US20110312954A1 (en) | 2011-12-22 |
| KR20110124305A (ko) | 2011-11-16 |
| CN102333773B (zh) | 2014-04-16 |
| CA2751901A1 (en) | 2010-09-16 |
| US8658638B2 (en) | 2014-02-25 |
| EP2406252B1 (en) | 2015-05-20 |
| ES2542001T3 (es) | 2015-07-29 |
| AU2010222902A1 (en) | 2011-08-11 |
| EA201171125A1 (ru) | 2012-02-28 |
| CN102333773A (zh) | 2012-01-25 |
| WO2010104721A1 (en) | 2010-09-16 |
| EA019179B1 (ru) | 2014-01-30 |
| EP2406252A1 (en) | 2012-01-18 |
| JP2012520302A (ja) | 2012-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0911563A2 (pt) | uso de antagonista da progesterona | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI1012676A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1012560A2 (pt) | anticorpos anti-fcrh5 e imunoconjugados e métodos de uso | |
| BRPI1008060A2 (pt) | Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo. | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| HUS1800027I1 (hu) | Muszkarin receptor antagonista és béta-2-adrenoreceptor agonista kombinációi | |
| BRPI0914004A2 (pt) | agentes de aglutinação de receptor notch1 e métodos de uso mesmo | |
| PT2513093E (pt) | Novos antagonistas do receptor ccr2 e suas utilizações | |
| PT2585437E (pt) | Compostos de tioacetato, composições e métodos de uso | |
| BRPI0813627A2 (pt) | Peptídio antimicrobiano, composições e métodos de uso | |
| BRPI0906435A2 (pt) | anticorpos anti-cd79b e imunoconjugados e métodos de uso | |
| BRPI1007175A2 (pt) | Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso | |
| BR112014014547A2 (pt) | compostos antagonistas de e-selectina, composições e métodos de uso | |
| BR112012018329A2 (pt) | agentes de coloração e métodos de uso destes | |
| BRPI1011321A2 (pt) | dispositivo de monitoramento de analito de métodos de uso | |
| ECSP12012034A (es) | Antagonistas de pcsk9 | |
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| BRPI0915717A2 (pt) | ferramenta de avaliação de cascalho e métodos de uso | |
| DOP2011000059A (es) | Composiciones de antagonistas de pd-1 y metodos de uso | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| BRPI1014544A8 (pt) | anticorpos anti-il-17f e metodos de uso dos mesmos | |
| BRPI0915086A2 (pt) | detecção do uso de canabis | |
| BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
| BR112012005736A2 (pt) | di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |